ATLANTA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC reminds investors that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) ( ALDX). The lawsuit alleges Aldeyra made materially false and/or misleading statements and/or failed to disclose material adverse facts about the Company’s business, operations, and compliance policies, including: (i) the ADX-2191 new drug application (“NDA”) did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191’s effectiveness; (ii) as a result, the FDA was unlikely to approve the ADX-2191 NDA in its current form; and (iii) accordingly, the Company had overstated ADX-2191’s clinical and/or commercial prospects.
If you bought shares of Aldeyra between March 17, 2022 and June 20, 2023, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey Holzer, Esq. [email protected] or Joshua Karr, Esq. at [email protected], by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at https://holzerlaw.com/case/aldeyra/ to learn more.
The deadline to ask the court to be appointed lead plaintiff in the case is September 29, 2023.
Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021 and 2022, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content. 
CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
[email protected]
